Fate Therapeutics Management
Management criteria checks 3/4
Fate Therapeutics' CEO is J. Wolchko, appointed in Dec 2015, has a tenure of 8.92 years. total yearly compensation is $3.52M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $608.19K. The average tenure of the management team and the board of directors is 6.8 years and 13.8 years respectively.
Key information
J. Wolchko
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 18.3% |
| CEO tenure | 8.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 6.8yrs |
| Board average tenure | 13.8yrs |
Recent management updates
Recent updates
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$190m |
| Dec 31 2023 | US$4m | US$645k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$173m |
| Jun 30 2023 | n/a | n/a | -US$212m |
| Mar 31 2023 | n/a | n/a | -US$235m |
| Dec 31 2022 | US$8m | US$645k | -US$282m |
| Sep 30 2022 | n/a | n/a | -US$294m |
| Jun 30 2022 | n/a | n/a | -US$254m |
| Mar 31 2022 | n/a | n/a | -US$233m |
| Dec 31 2021 | US$12m | US$610k | -US$212m |
| Sep 30 2021 | n/a | n/a | -US$197m |
| Jun 30 2021 | n/a | n/a | -US$212m |
| Mar 31 2021 | n/a | n/a | -US$185m |
| Dec 31 2020 | US$6m | US$570k | -US$173m |
| Sep 30 2020 | n/a | n/a | -US$149m |
| Jun 30 2020 | n/a | n/a | -US$117m |
| Mar 31 2020 | n/a | n/a | -US$112m |
| Dec 31 2019 | US$11m | US$540k | -US$98m |
| Sep 30 2019 | n/a | n/a | -US$86m |
| Jun 30 2019 | n/a | n/a | -US$76m |
| Mar 31 2019 | n/a | n/a | -US$72m |
| Dec 31 2018 | US$4m | US$516k | -US$67m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$57m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$1m | US$480k | -US$43m |
Compensation vs Market: J.'s total compensation ($USD3.52M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
CEO
J. Wolchko (54 yo)
8.9yrs
Tenure
US$3,522,750
Compensation
Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015 & serves as It's CFO and CAO since June 3, 2024. Mr. Wolchko ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.9yrs | US$3.52m | 0.24% $ 608.2k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 9.1yrs | US$2.82m | 0.053% $ 133.8k | |
| President of Research & Development | 6.8yrs | US$2.99m | 0.067% $ 168.6k | |
| Chief Regulatory & Quality Officer | 2.8yrs | no data | 0.24% $ 613.1k | |
| Senior Vice President of Clinical Operations | less than a year | no data | no data |
6.8yrs
Average Tenure
52.5yo
Average Age
Experienced Management: FATE's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.1yrs | US$3.52m | 0.24% $ 608.2k | |
| Independent Chairman | 13yrs | US$253.25k | 0.54% $ 1.4m | |
| Independent Vice Chairman of the Board | 16.6yrs | US$218.33k | 0.27% $ 690.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.7yrs | US$228.25k | 0.010% $ 25.2k | |
| Member of Scientific Advisory Board | 14.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 14.5yrs | no data | no data | |
| Independent Director | 11.3yrs | US$231.75k | 0.058% $ 147.2k | |
| Member of Scientific Advisory Board | 14.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 14.5yrs | no data | no data | |
| Independent Director | 5.7yrs | US$227.82k | 0.0086% $ 21.9k |
13.8yrs
Average Tenure
66.5yo
Average Age
Experienced Board: FATE's board of directors are seasoned and experienced ( 13.8 years average tenure).